Table 2 Treatment related characteristics affecting overall and local recurrence-free survival outcomes.

From: Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients

Characteristics

N.

%

Overall Survival (OS)

Local Recurrence Free survival (LRFS)

Univariate

Multivariate analysis

Univariate

Multivariate analysis

p-value

Patients

Events

HR

95% CI

Test C-index

p-value

Patients

Events

HR

95% CI

Test C-index

IRS Post-Surgical Group

Group I

173

31.3

 < 0.001

253

73

0.41

0.21–0.77

76%

 < 0.001

320

73

0.47

0.261–0.84

72%

Group I-II

57

10.3

      

0.129

320

73

0.63

0.307–1.30

72%

Group II

55

9.9

      

0.018

320

73

1.79

0.975–3.26

72%

Group III

168

30.4

            

Treatment Modality

Trimodality

139

25.1

0.225

253

73

0.82

0.47–1.40

76%

0.437

320

73

0.74

0.415–1.30

70%

Surgery and chemotherapy

152

27.5

0.001

253

73

0.99

0.54–1.79

76%

0.070

320

73

0.97

0.551–1.72

71%

Surgery alone

105

19.0

0.067

253

73

0.94

0.44–2.01

77%

0.096

320

73

0.98

0.520–1.84

71%

Surgery and radiotherapy

62

11.2

0.953

253

73

1.24

0.55–2.77

76%

0.588

320

73

0.98

0.465–2.05

71%

Radio and Chemotherapy

73

13.2

      

0.869

320

73

1.17

0.57–2.382

71%

Chemo Only or Radio Only

21

3.8

            

Chemotherapy Use

377

68.2

0.023

253

73

0.89

0.46–1.70

76%

0.013

320

73

0.79

0.45–1.367

70%

Category of Chemotherapy

Cyclo based

84

22.5

0.593

185

55

1.51

0.71–3.18

73%

0.746

224

46

1.39

0.68–2.855

70%

Cyclo and Anthracycline based

79

21.2

0.002

185

55

0.54

0.24–1.21

72%

0.017

224

46

0.46

0.191–1.11

73%

Ifo and Anthracycline based

52

13.9

0.443

185

55

1.46

0.75–2.82

75%

0.999

224

46

1.23

0.536–2.80

71%

Anthracycline based

18

4.8

0.012

185

55

1.68

0.50–5.53

74%

0.076

224

46

2.77

1.059–7.24

70%

Ifo based

15

4.0

            

Cyclo and Ifo and Anthracycline

15

4.0

            

Vincristine/VA only

33

8.8

            

Unknown

77

20.6

            

Timing of Chemotherapy

Neoadjuvant

26

5.1

0.040

247

70

0.55

0.15–1.90

76%

      

Adjuvant

219

42.9

 < 0.001

247

70

1.10

0.66–1.84

75%

0.039

312

70

0.83

0.490–1.41

71%

Both pre and post-surgery

15

2.9

0.059

247

70

0.23

0.03–1.63

76%

      

Primary modality

78

15.3

      

0.634

312

70

1.16

0.572–2.36

72%

Response to chemotherapy

Complete response (CR)

51

9.2

 < 0.001

250

72

0.18

0.05–0.58

79%

0.007

317

73

0.24

0.073–0.78

73%

Disease progression (PD)

35

6.3

 < 0.001

250

72

4.34

2.23–8.41

80%

 < 0.001

317

73

3.60

1.567–8.28

73%

Partial response (PR)

34

6.1

      

0.013

317

73

2.21

1.096–4.47

70%

Stable disease (SD)

8

1.4

            

Not available (N/A)

87

15.7

            

Not applicable

334

60.4

            
  1. aBold = significant values (p < 0.05); Cyclo: Cyclophosphamide; Ifo: Ifosfamide; VA: Vincristine, Actinomycin-D. For the multivariate models, each variable was adjusted to the following set of covariates: OS analysis: Age, UICC stage I, GU (B/P), IRS Post-Surgical Group-I and IRS risk group; LRFS analysis: Age, IRS Post-Surgical Group-I, IRS Post-Surgical Group-II and IRS risk group. Empty rows correspond to covariates that were not entered into the model because they were either explained by other covariates or did not meet the model inclusion criteria (due to small number of events or other reasons - see Methodology section for details).
Back to article page